UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen
receptor in patients with EGFRvIII+ glioblastoma.
Authors*: Donald M. O’Rourke, MacLean Nasrallah, Jennifer J. Morrissette, Jan J. Melenhorst,
Simon F. Lacey, Keith Mansfield, Maria Martinez-Lage, Arati Suvas Desai, Steven Brem, Eileen Maloney,
Suyash Mohan, Sumei Wang, Gaurav Verma, Jean-Marc Navenot, Angela Shen, Zhaohui Zheng,
Bruce Levine, Hideho Okada, Carl H. June, Marcela Valderrama Maus
Abstract #: 2067
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM
Location: Hall A, Poster Board # 254
Session: Central Nervous System Tumors
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2067)
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on
development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada
conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the
first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also
delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient
trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of
vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric
antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html
*UCSF authors in bold
22